Blue Crest Capital Management LTD Nektar Therapeutics Transaction History

Blue Crest Capital Management LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $133,859 - $287,113	-7,916 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $245,396 - $287,350	7,916 New	7,916 $282,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $976,224 - $1.82 Million	-32,081 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $5.85 Million - $8.62 Million	-125,850 Reduced 79.69%	32,081 $1.96 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $6.97 Million - $15.7 Million	150,738 Added 2095.62%	157,931 $7.71 Million

Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $412,878 - $780,008	7,193 New	7,193 $764,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $231M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.